AIM Vaccine Co., Ltd. (HKG:6660)
Hong Kong
· Delayed Price · Currency is HKD 3.670
+0.040 (1.10%)
Jun 23, 2025, 3:59 PM HKT
AIM Vaccine Revenue
In the year 2024, AIM Vaccine had annual revenue of 1.29B CNY with 8.22% growth. AIM Vaccine had revenue of 747.85M in the half year ending December 31, 2024, with 11.20% growth.
Revenue
1.29B CNY
Revenue Growth
+8.22%
P/S Ratio
3.29
Revenue / Employee
837.15K CNY
Employees
1,535
Market Cap
4.50B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Akeso | 2.26B |